Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...

New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone. A new global commercial partnership between Boehringer Ingelheim...

Boehringer expands production site in Greece for new medicine Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the...